Business context and reporting period
This is Gemini Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2021, filed August 12, 2021. The request metadata names Disc Medicine, Inc.; that does not match the registrant identified in the filing. Gemini was a clinical-stage biotechnology company developing therapies for genetically defined age-related macular degeneration. Its lead candidate, GEM103, was in Phase 2a development; other programs were preclinical or earlier. The company had no approved products or product revenue.
On February 5, 2021, Gemini completed a business combination with FS Development Corporation and a concurrent PIPE financing. It accounted for the transaction as a reverse recapitalization and received approximately $195.9 million in net proceeds.
Financial performance and position
Amounts below are in millions of dollars, except per-share data. The company reported no revenue, so gross margin and operating margin are not meaningful.
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Research and development | $10.8 | $5.5 | $22.6 | $13.7 |
| General and administrative | $5.5 | $1.1 | $10.2 | $2.6 |
| Total operating expenses | $16.3 | $6.7 | $32.8 | $16.3 |
| Net loss | $(16.4) | $(6.8) | $(35.5) | $(16.5) |
| Net loss per share, basic and diluted | $(0.38) | $(0.44) | $(0.94) | $(1.11) |
| Cash used in operating activities | Not separately stated | Not separately stated | $(30.9) | $(16.9) |
At June 30, 2021, cash and cash equivalents were $167.5 million (plus $0.3 million restricted cash), compared with $4.5 million and $0.3 million, respectively, at December 31, 2020. Total assets were $172.4 million; current assets were $171.3 million and current liabilities $11.5 million. Stockholders’ equity was $157.7 million, versus a deficit of $21.9 million at year-end. Accumulated deficit was $148.3 million.
Term-loan principal outstanding was $7.9 million, including $5.0 million current and $2.9 million long-term carrying value. The loan matures January 1, 2023; its floating rate was the greater of 3.75% or prime less 1.5%. Convertible notes outstanding at year-end converted into preferred stock before the business combination and were no longer liabilities at June 30.
Material changes versus comparable periods
- Q2 operating expenses rose $9.7 million year over year and net loss widened $9.7 million. For the first six months, operating expenses increased $16.5 million and net loss widened $19.0 million.
- Management attributed higher R&D costs mainly to GEM103 clinical-trial activity and increased R&D headcount. Higher G&A reflected organizational growth, stock-based compensation, and public-company legal and professional costs.
- Six-month interest expense rose to $2.0 million from $0.3 million, primarily due to accretion of the convertible-note discount; the company also recorded a $0.7 million loss on conversion of those notes.
- Financing cash flow was $193.9 million in the first half of 2021, principally reflecting business-combination proceeds, versus $20.1 million in 2020, mainly from preferred-stock issuance. Operating cash use increased to $30.9 million from $16.9 million.
Outlook, risks, and unusual items
Management said cash and cash equivalents were expected to fund operating expenses and capital requirements into 2023, while the financial-statement note separately states cash was expected to fund planned operations for at least 12 months from issuance of the statements. These are management estimates and may change; additional financing may be required. The company expects continued losses and rising R&D and G&A costs, and cannot predict when, or whether, it will become profitable.
Key risks include clinical and regulatory uncertainty, trial enrollment and data quality, reliance on third-party manufacturers and research organizations, funding needs, intellectual-property protection, competition, and the ability to recruit and retain personnel. COVID-19 had no significant impact on Q2 financial results according to management, but had slowed trial data collection and could disrupt supplies, recruitment, retention, trial timelines, or data quality. The company reported no material legal proceedings, no material changes to previously disclosed risk factors, and no off-balance-sheet arrangements.
Unusual transaction-related items include $195.9 million of net business-combination proceeds and $21.0 million of transaction costs recorded as a reduction to additional paid-in capital. The filing reported effective disclosure controls and no material changes in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the registrant identity: this filing is for Gemini Therapeutics, Inc., not Disc Medicine, Inc.
- Review GEM103 trial progress, timing, enrollment, and data quality, including potential COVID-19 effects.
- Assess the assumptions supporting the stated cash runway into 2023 and the pace of operating cash use.
- Track clinical-development spending, public-company costs, and potential need for additional capital or dilution.
- Review the term-loan repayment schedule, floating interest rate, and January 2023 maturity.